Previous Article | Next Article 
J Virol, May 1998, p. 4379-4386, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Borna Disease Virus-Induced Neurological Disorder
in Mice: Infection of Neonates Results in Immunopathology
Wiebke
Hallensleben,1
Martin
Schwemmle,1
Jürgen
Hausmann,1
Lothar
Stitz,2
Benedikt
Volk,3
Axel
Pagenstecher,3 and
Peter
Staeheli1,*
Abteilung Virologie, Institut für
Medizinische Mikrobiologie & Hygiene, Universität Freiburg, 79008 Freiburg,1
Institut für
Neuropathologie, Universität Freiburg, 79106 Freiburg,3 and
Institut für
Impfstoffe, Bundesforschungsanstalt für Viruskrankheiten der
Tiere, 72076 Tübingen,2 Germany
Received 17 December 1997/Accepted 2 February 1998
 |
ABSTRACT |
Borna disease virus (BDV) is a neurotropic nonsegmented
negative-stranded RNA virus that persistently infects warm-blooded animals. In horses and other natural animal hosts, infections with BDV
cause meningoencephalitis and behavioral disturbances. Experimental
infection of adult mice takes a nonsymptomatic course, an observation
previously believed to indicate that this animal species is not
suitable for pathogenesis studies. We now demonstrate that BDV
frequently induces severe neurological disease in infected newborn
mice. Signs of neurological disease were first observed 4 to 6 weeks
after intracerebral infection. They included a characteristic nonphysiological position of the hind limbs at an early stage of the
disease and paraparesis at a later stage. Histological examination
revealed large numbers of perivascular and meningeal inflammatory cells
in brains of diseased mice and, unexpectedly, no increase in
immunoreactivity to glial fibrillar acidic protein. The incidence and
severity of BDV-induced disease varied dramatically among mouse
strains. While only 13% of the infected C57BL/6 mice showed disease
symptoms, which were mostly transient, more than 80% of the infected
MRL mice developed severe neurological disorder. In spite of these
differences in susceptibility to disease, BDV replicated to comparable
levels in the brains of mice of the various strains used. Intracerebral
infections of newborn
2-microglobulin-deficient C57BL/6 and MRL
mice, which both lack CD8+ T cells, did not result in
meningoencephalitis or neurological disease, indicating that the
BDV-induced neurological disorder in mice is a cytotoxic
T-cell-mediated immunopathological process. With this new animal model
it should now be possible to characterize the disease-inducing immune
response to BDV in more detail.
 |
INTRODUCTION |
Borna disease has been described as
a progressive nonpurulent meningoencephalomyelitis of horses and
sheep with various clinical symptoms ranging from slightly impaired
coordination to paralysis and death (17, 26, 36). This
disease is caused by Borna disease virus (BDV), a nonsegmented
negative-stranded RNA virus (13, 41, 46). A wide variety of
animal species have been successfully infected with BDV, and persistent
infection of neuronal tissue is usually achieved (17, 36).
Most studies of the pathogenesis of Borna disease were performed with
Lewis rats, which are highly susceptible to the deleterious effects of
BDV (17, 26, 28, 36, 43). By contrast, persistently infected
mice were reported to exhibit only barely detectable clinical symptoms
(22, 40). BDV or a related virus may be associated with
psychiatric disorders in humans (4, 5, 23, 37, 38, 46).
In rats, the clinical course and histopathology of Borna disease vary
with the age of the animal at the time of infection. In adult Lewis
rats, BDV infection results in severe encephalitis accompanied by
clinical symptoms that include hyperactivity, aggressiveness, and
ataxia (17, 36). At a later stage of the disease, surviving animals are apathetic and show signs of dementia and behavioral abnormalities, and their brains show a dramatic loss of neuronal tissue
(3, 17, 19, 28, 36). BDV-induced encephalitis can be
prevented by immunosuppressive drugs and can be induced in drug-treated
rats by adoptive transfer of immune lymphocytes (29, 35,
45), suggesting that immunopathological mechanisms play a key
role in the disease process. Borna disease in rats is a
CD4+ T-cell-dependent immunopathological disorder in which
CD8+ T-cell-mediated mechanisms are operative (32, 33,
35). In newborn Lewis rats, exposure to BDV results in persistent
infection of the neuronal tissue and other cell types but few
infiltrating lymphocytes are observed histologically (19,
29). Nonetheless, severe hippocampus damage occurs in
persistently infected rats and pronounced learning deficiencies are
observed (10, 15, 19). Several studies indicated that
BDV-induced soluble factors may negatively influence the clinical
course of neurological disease. For example, it was found that
tolerant, persistently infected Lewis rats developed severe clinical
symptoms but only mild encephalitis when connected by parabiosis to
rats with Borna disease (10), indicating that cytokines and
other soluble factors produced in the brain of the ill animal reached
the brain of the acceptor animal and disturbed its function. In fact,
potentially toxic nitric oxide and proinflammatory cytokines were
detected in the brains of BDV-infected rats (42, 47).
To identify the disease-inducing components of the immune system and
the cytokine network, an animal model that is accessible to genetic
manipulation is urgently needed. Here we show that infection of newborn
but not adolescent mice with BDV can induce a CD8+
T-cell-dependent immunopathological process that results in severe neurological disease.
 |
MATERIALS AND METHODS |
Mice.
Breeding pairs of BALB/c, C57BL/6, C3H, and CBA mice
were purchased from Charles River, Sulzfeld, Germany. Breeding pairs of
wild-type MRL/MpJ and
2-microglobulin-deficient MRL/MpJ-B2m mice
were purchased from Jackson Laboratory, Bar Harbor, Maine. Breeding
pairs of
2-microglobulin-deficient C57BL/6J-B2m were purchased from
Bomholtgard Breeding and Research Centre Ltd, Ry, Denmark. All
breedings were done in our local animal facility.
Virus stocks.
A stock of BDV rat He/80 was prepared from
brains of persistently infected 4-week-old Lewis rats that were
infected with BDV as newborns (44). It represented the
fourth continuous passage of the virus in brains of newborn rats.
Stocks of BDV mouse He/80 were prepared from brains of 4- to 6-week-old
diseased BALB/c mice that were infected with BDV as newborns. The
stocks of mouse-adapted BDV used for the experiments described here
were from the second, third, and fourth passages of original BDV rat
He/80 in mouse brains. To prepare virus stocks, brains were homogenized
by douncing in phosphate-buffered saline (PBS) as 10% (wt/vol)
suspensions. After freezing and thawing, the material was centrifuged
at 4°C for 5 min at 10,000 rpm in an Eppendorf microcentrifuge, and
samples of the supernatant were stored as 100-µl aliquots at
70°C. A new aliquot of this virus stock was used for each infection
experiment. The stock of BDV rat He/80 titered on C6 rat glioblastoma
cells contained approximately 106 focus-forming units (FFU)
of virus per ml. The stocks of BDV mouse He/80 contained between 1 × 104 and 2 × 105 FFU of virus per ml.
Titrations of BDV on C6 glioblastoma cells.
Semiconfluent
monolayers of C6 cells on glass coverslips in Dulbecco's modified
essential medium supplemented with 10% fetal calf serum were incubated
with various dilutions of the virus stocks. After 4 days at 37°C, the
cells were fixed with 3% paraformaldehyde for 10 min, permeabilized
for 5 min with 0.5% Triton X-100, and analyzed for the presence of
cells expressing virus antigen by indirect immunofluorescence
(9) using 0.2% serum from BDV-infected BALB/c mice. Virus
titers were calculated by assuming that each focus of fluorescent cells
originated from infection with a single replication-competent virus
particle.
BDV infections of mice.
Samples (approximately 10 µl) of
undiluted virus stocks were injected intracerebrally with a Hamilton
syringe. Sham infections were performed with brain extracts from
uninfected BALB/c mice that were processed as described above for virus
stocks (10% [wt/vol] suspensions).
Monitoring infected mice for disease symptoms.
Mice were
examined daily for neurological symptoms. To check for the
characteristic unphysiological hind limb position of symptomatic
animals (see Fig. 1), the mice were held up by the tail for
approximately 5 seconds. To monitor the general health status of the
infected mice, the animals were weighed daily starting at about 2 weeks
postinfection.
Analyzing serum samples for BDV-specific antibodies.
Blood
samples (3 µl) were taken from the tail veins of infected mice and
diluted in 100 µl of PBS. To detect antibodies to viral proteins, the
samples were centrifuged and supernatants were allowed to react for
1 h at 25°C with C6 cells persistently infected with BDV
(11). The cells were grown on glass coverslips, fixed for 10 min with 3% paraformaldehyde, and permeabilized for 5 min with 0.5%
Triton X-100. After being extensively washed with PBS, bound antibodies
were visualized with 1% fluorescein-labelled goat anti-mouse
immunoglobulin G (IgG). Under these conditions, prominent staining of
dot-like structures in the nuclei of infected cells was evident in
blood samples containing BDV-specific antibodies.
Northern blot analysis for detecting BDV in mouse brain
tissue.
Complete hemispheres of mouse brains were used to prepare
total RNA as previously described (12). For Northern blot
analysis, 10-µg samples of RNA were electrophoresed through a 1.2%
agarose-formaldehyde gel, transferred to a nitrocellulose membrane, and
hybridized under standard conditions with a radiolabelled cDNA probe
(nucleotides 3 to 1873) that roughly corresponds to the
nonpolyadenylated 1.9-kb viral transcript found in BDV-infected
cells (7). This cDNA fragment was generated by reverse
transcription-PCR with an appropriate pair of primers and RNA from C6
cells persistently infected with BDV (11). The membrane was
washed at high stringency and exposed to X-ray film. To verify that a
comparable amount of RNA was loaded in each lane, the membrane was
stripped and reprobed with a radiolabelled glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA probe (30) under standard
conditions (2). Quantitation was done by determining the
radioactivity that remained bound to the membranes after stringent washing by using a Fujix BAS 1000 bio-imaging analyzer (Raytest, Straubenhardt, Germany). The BDV-specific hybridization signal of each
lane was corrected for uneven loading of RNA by normalizing the value
to the GAPDH signal.
Histological analysis of brain sections.
Mice were
sacrificed under ether anaesthesia. One complete brain hemisphere was
fixed in Zamboni's reagent (4% paraformaldehyde and 15% picric acid
in 0.25 M sodium phosphate, pH 7.5) and embedded in paraffin. Sagittal
sections approximately 4-µm thick were stained with hematoxylin and
eosin and examined under a light microscope. Immunostainings of
tissue sections for viral antigen and glial fibrillar acidic protein
(GFAP) were done with 0.2% monospecific rabbit antiserum to BDV p40 (a
generous gift from I. Lipkin, Irvine, Calif.) and 0.05% polyclonal
antibody against bovine GFAP (purchased from Dako, Hamburg, Germany),
respectively. After being extensively washed, bound antibodies were
identified with peroxidase-labeled antisera with the Vectastain reagent
kit (Camon, Wiesbaden, Germany).
 |
RESULTS |
Differences among mouse strains in frequency of BDV-induced
neurological disease in newborns.
Intracerebral injection of
standard preparations of BDV fails to induce disease in adult
laboratory mice (22). In a recent study (40),
mild signs of neurological disease were observed when mouse-adapted BDV
was used to infect adult mice of strain MRL. We therefore examined
whether newborn mice might exhibit greater susceptibility to
BDV-induced neurological disease than adult mice and whether
differences in susceptibility might exist among mouse strains. Newborn
mice were given intracerebral injections of 10-µl samples of 10% rat
brain homogenates containing about 104 FFU of BDV strain
He/80. The injected material was from the fourth passage of the virus
in brains of newborn rats. Virus infection of newborn mice resulted in
severe neurological disease in some but not all animals (Table
1). Affected animals could easily be
identified at an early stage of the virus-induced disease by a
characteristic nonphysiological position of the hind limbs: when lifted
by their tails, they drew their limbs in towards their bodies (Fig.
1A), in contrast to the full extension of
limbs observed with nonsymptomatic littermates (Fig. 1B). A similar
disease phenotype was previously observed in mice with targeted
disruptions of the neurotrophin-3 receptor gene (24), the
A-raf protein kinase gene (34), and the Huntington's
disease gene (27), indicating that this phenotype is a
sensitive but rather nonspecific indicator of pathological changes in
the brain. The affected animals further exhibited a characteristic
hunched posture, had a rough fur, and often presented with tilted
heads. Neurological disease typically progressed fast and coincided
with a pronounced loss of body weight of usually more than 20% in 4 days (see Fig. 5). Some animals recovered partially or completely from
this acute phase of BDV-induced disease, while others failed to regain
weight and started to show progressive paraparesis of the hind limbs.
If not sacrificed, these animals eventually died, presumably because
they were no longer able to eat and drink.

View larger version (171K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Characteristic nonphysiological position of the hind
limbs of a BDV-infected MRL mouse with early signs of neurological
disease. (B) Position of the hind limbs of a nonsymptomatic
littermate.
|
|
The percentages of animals showing the above-described signs of
neurological disease differed widely among inbred mouse strains (Table
1). Mice of strain MRL were most susceptible to BDV-induced disease:
83% of the virus-infected animals presented with severe neurological
disease between 27 and 43 days postinfection. Although smaller
percentages of the infected C3H and CBA mice turned ill (47 and 36%,
respectively), the affected individuals of these two strains showed
signs of neurological disease that were about as strong as those of
diseased MRL mice. About 34 and 13% of the infected BALB/c and C57BL/6
mice, respectively, showed clear signs of neurological disease at 3 to
6 weeks postinfection (Table 1). However, unlike mice of strains MRL,
C3H, and CBA, only a small percentage of the infected BALB/c and
C57BL/6 mice that exhibited clear signs of neurological disease went on
to develop a life-threatening illness. Furthermore, the disease often
progressed more slowly in the latter animals, and many BALB/c and
C57BL/6 mice recovered partially or completely from the acute phase of
disease by about 2 weeks post onset of first symptoms.
When BDV was adapted to grow in mouse brains by serial passage in
newborn BALB/c mice, the picture did not change much. Between
36 and
57% of the animals used for each of the four passages came
down with
disease. When second-passage virus was used to infect
newborn MRL mice
intracerebrally, 11 of the 12 animals developed
signs of severe
neurological disease after 27 to 42 days (Table
2). These results indicated that
adaptation of BDV to mice had
not greatly altered its pathogenicity. To
evaluate the possibility
that the brain homogenate rather than the
virus induced disease
in our mice by autoimmunological mechanisms,
seven MRL mice were
sham infected with 10% extracts prepared from
brains of uninfected
mice. No neurological disease symptoms were
recorded in these
mice during the observation period of 10 weeks (data
not shown).
Lymphocytic meningoencephalitis without increased GFAP
immunoreactivity in brains of diseased mice.
Brains of
BDV-infected mice were subjected to histological examination at various
stages of the disease. Sections through the neocortex revealed signs of
severe lymphocytic meningoencephalitis in brains of animals with overt
disease. The severely diseased MRL mice presented with serious
meningitis and prominent perivascular lymphocytic infiltrations of the
brain (Fig. 2B).
Furthermore, the numbers of neurons were decreased. The histological
features of the cortex in age-matched uninfected mice were
inconspicuous (Fig. 2A). Brains of diseased BALB/c mice showed similar
but usually milder histopathological features than those of diseased
MRL mice (data not shown). Brains of infected mice without noticeable
signs of neurological disease rarely contained infiltrating lymphocytes as determined by hematoxylin and eosin staining (data not shown). Thus,
the overall extent of inflammation in the brains of the infected
animals correlated well with the score of clinical symptoms.

View larger version (87K):
[in this window]
[in a new window]
|
FIG. 2.
Pathological alterations and virus distribution in
brains of BDV-infected MRL mice possessing or lacking a functional
2-microglobulin gene. Brain sections from an uninfected healthy MRL
control mouse (A, D, G, J), from a BDV-infected wild-type MRL mouse
with severe signs of neurological disease (B, E, H, K), and from a
BDV-infected healthy MRL mouse lacking 2-microglobulin (C, F, I, L)
were compared. Staining with hematoxylin and eosin (panels A to C)
revealed strong meningitis and prominent perivascular lymphocytic
infiltrates in the neocortex of the diseased animal, whereas the
corresponding brain regions of the uninfected healthy control animal
and of the infected 2-microglobulin-deficient ( 2mo/o)
MRL mouse were inconspicuous. Immunostaining of tissue sections for BDV
p40 (panels D to I) showed similar numbers of infected neurons in the
thalami (panels G to I) of the wild-type and mutant mice. By contrast,
fewer infected neurons were present in the neocortex (panels D to F) of
the diseased wild-type animal than in the neocortex of the healthy MRL
2mo/o mouse. Immunostaining failed to reveal signs of
increased GFAP expression in the brains of BDV-infected wild-type and
mutant mice (panels J to L) as usually seen in astrogliosis
(16). Corresponding areas of the hippocampus formation are
shown.
|
|
When the brain sections of diseased MRL mice were immunostained for
GFAP to assess the degree of astrogliosis, very little
specific
staining was observed (Fig.
2K). In fact, GFAP expression
in these
brains did not exceed the constitutive expression observed
in
uninfected mice (Fig.
2J). When brain sections were immunostained
for
the p40 antigen of BDV, we observed that the cortical brain
areas of
diseased mice which harbored high numbers of lymphocytes
contained only
a few BDV-infected neurons (Fig.
2E) compared to
those contained in the
corresponding regions of nonsymptomatic
mice (Fig.
2F) or the thalamus
region (Fig.
2H), which usually
revealed no inflammatory foci. This
inverse correlation between
lymphocytic infiltrations and presence of
BDV-infected neurons
suggested that the antiviral immune response had
selectively removed
infected neurons.
Kinetics of BDV replication in brains of infected newborn
mice.
To determine the kinetics of BDV replication in brains of
infected mice, we measured the concentrations of BDV-specific
transcripts by Northern blot analysis at various times after
intracerebral infection of newborns. No or only very low levels of
BDV-specific RNAs were observed by this method in brains of MRL or
BALB/c mice that were infected for less than 15 days, while viral RNAs
could easily be detected in brains of mice that were infected with BDV for 20 days or longer (Fig. 3). The
concentration of viral RNAs in brains of infected mice seemed to reach
a plateau at approximately 4 weeks postinfection, and it seemed to be
maintained at this high level for at least 12 months in nonsymptomatic
BALB/c mice (Fig. 3B). In the experiment shown in Fig. 3A, one of the
infected MRL mice showed typical signs of severe BDV-induced
neurological disease at 28 days postinfection. Quantitative analysis of
the Northern blot signals revealed that the diseased animal contained at least sixfold less viral RNA in the brain than a nondiseased littermate that was sacrificed at the same time (Fig. 3A). A similar picture was observed in a pair of diseased and nondiseased MRL mice
that was sacrificed at day 32 postinfection (Fig. 3A). Likewise, a
BALB/c mouse which showed clear signs of neurological disease at day 28 postinfection contained severalfold less viral RNAs than an infected
BALB/c mouse that remained nonsymptomatic for 28 days (Fig. 3B).
Similar findings were made in other experiments with pairs of diseased
and nondiseased littermates of strains MRL and CBA (Fig.
4). Occasionally, however, as for example
in a pair of diseased and nondiseased C3H mice (Fig. 4), the animal showing strong signs of neurological disease contained equal or even
slightly higher levels of viral transcripts. Thus, in most but not all
cases we found an inverse correlation between the presence of high
levels of viral RNAs and signs of neurological disease, suggesting that
(i) virus replication in cells of the central nervous system (CNS) per
se did not cause the disease which we observed in our infected animals
and that (ii) the antiviral activity of the immune system eliminated
virus-infected cells and induced disease.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Time course of BDV replication in brains of infected MRL
(A) and BALB/c (B) mice. Animals were infected as newborns with
104 FFU of BDV He/80 by the intracerebral route. At the
indicated times after infection, randomly selected animals were
sacrificed, RNA was prepared from complete brain hemispheres, and
10-µg samples were assayed for the presence of BDV-specific
transcripts by Northern blot analysis. BDV-specific transcripts of 0.8, 1.2, and 1.9 kb were visualized by hybridization to a radiolabeled cDNA
probe comprising nucleotides 2 to 1873 of the BDV genome. After
stripping, the membrane was rehybridized to a radiolabeled GAPDH cDNA
probe to verify that similar amounts of RNA were present in the various
lanes. Animals with (+) and without ( ) typical signs of neurological
disease were evaluated. The symbol "+*" indicates that the animal
had shown typical signs of neurological disease at approximately 5 weeks postinfection. Such animals recovered from the acute phase of
disease and were nonsymptomatic at the time of analysis.
|
|

View larger version (92K):
[in this window]
[in a new window]
|
FIG. 4.
Virus loads in brains of mice of strains differing in
resistance to BDV-induced disease. Mice of the MRL,
2-microglobulin-deficient ( 2mo/o) MRL, CBA, and
C3H strains were infected with BDV as newborns and sacrificed at the
age of about 4 to 6 weeks. Brain RNA samples were assayed for the
presence of BDV-specific transcripts as described in the legend for
Fig. 3. Littermates with (+) and without ( ) typical signs of
neurological disease were compared.
|
|
To determine whether the observed variations in susceptibility of
inbred mouse strains to BDV-induced neurological disease
simply
reflected differences in the rates at which BDV replicates
in the CNSs
of these animals, we compared the relative levels
of viral transcripts
in brains from nondiseased animals of strains
MRL, BALB/c, CBA, C3H,
and C57BL/6 that were infected as newborns
and sacrificed at the age of
4 to 6 weeks. Differences in viral
RNA contents of the various brains
were usually less than fivefold
(Fig.
4 and data not shown) and thus
not greater than those observed
between individuals of two litters of
the same mouse strain (reference
18 and unpublished
results). These differences probably cannot
explain the dramatic
differences in susceptibility to BDV-induced
disease between C57BL/6
and MRL mice.
Seroconversion coincides with the onset of BDV-induced
disease symptoms.
To learn more about the physiological
changes immediately preceding disease onset, we carefully monitored
health changes and weight gain disturbances of several MRL mice that
were infected as newborns with rat- or mouse-passaged BDV (litters 82 and 73, respectively). Starting from around day 18 postinfection, we
further collected blood samples for serological analysis every third
day. All mice gained weight at a fairly constant rate and looked
healthy until about day 28. Thereafter, most animals abruptly stopped gaining weight (Fig. 5 shows the charts
of animals 82A, 82B, 73A, and 73F) and started to hold their hind limbs
in a characteristic nonphysiological position (Fig. 1). Serological
analysis showed that all animals that developed these signs of
neurological disease had started to produce antibodies to BDV proteins
just prior to the onset of clinical disease (Fig. 5). Neurological
disease progressed rapidly in most of these animals so that they had to
be euthanatized. Some animals, including 73F which was infected with a
mouse-passaged BDV stock, continued to gain weight after 4 weeks of
age, showed no signs of neurological disease, and remained seronegative
during this period (Fig. 5). However, animal 73F abruptly lost weight at the age of about 6 weeks and started to show strong signs of neurological disease. Serological analysis revealed that, like its
littermates which became ill earlier, it had seroconverted shortly
before disease onset (Fig. 5). Thus, disease onset coincided with the
initial recognition of BDV by the immune system.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Onset of neurological disease in MRL mice coincides with
first appearance of serum antibodies to BDV. Newborn wild-type (litters
82 and 73) or 2-microglobulin-deficient (litter 90) MRL mice were
infected by the intracerebral route with either rat brain homogenate
containing 104 FFU of BDV He/80 (litters 82 and 90) or
mouse brain homogenate containing 2 × 103 FFU of BDV
He/80 (litter 73). Infected animals were weighed daily and examined for
the appearance of signs of neurological disease. Blood samples were
analyzed for the presence of BDV-specific antibodies. The charts of two
animals from each litter are shown. The shaded areas mark periods of
overt neurological disease. The arrows mark the first detection of
BDV-specific antibodies in serum samples. The crosses indicate when the
diseased animals were euthanatized. The sudden weight gain of animal
90B towards the end of the observation period was due to pregnancy.
|
|
No disease in BDV-infected mice lacking CD8+ T
cells.
Massive mononuclear cell infiltrates in brains from
diseased mice and the fact that serum antibodies to BDV started to
appear in infected mice shortly before disease onset both suggested
that immunopathological processes were at work. Since CD8+
T cells play a key role in the BDV-induced neurological disease of rats (33), we tested whether the symptoms would be milder or even absent in infected mice lacking this T-cell population. Mice with a targeted disruption of the
2-microglobulin gene fail to
express major histocompatibility complex (MHC) class I antigen and, as a consequence, lack CD8+ T cells (25,
48). In a first experiment, we infected newborn
2-microglobulin-deficient C57BL/6 mice with the standard dose of BDV
(10 µl of stock He/80 prepared from brains of infected newborn rats)
by the intracerebral route. None of the 23 infected animals developed
signs of neurological disease within the 12-week observation period.
Serum antibodies to viral proteins were detectable in all infected
2-microglobulin-deficient mice, but they appeared later (usually not
before 7 weeks postinfection) and reached lower titers than in
wild-type mice (data not shown). This latter phenotype can be explained
by the fact that
2-microglobulin is a component of the protection
receptor for IgG catabolism that enhances the serum half-life of IgG
molecules (20): mice lacking
2-microglobulin have greatly
reduced levels of IgG but not IgA.
To confirm the notion that BDV-induced neurological disease in mice was
dependent on CD8
+ T cells, we also infected

2-microglobulin-deficient MRL mice,
which genetic background, as
shown above, strongly predisposes
for BDV-induced disease. All 38 infected MRL mice with this genetic
defect remained healthy and did not
show signs of neurological
disease within the observation period of 6 to 12 weeks, indicating
that CD8
+ cytotoxic T cells are
indeed instrumental for neurologic disorder
in BDV-infected mice.
Northern blot analysis of brain RNAs indicated
that BDV replicated to
comparable levels in the CNSs of mutant
and wild-type mice (Fig.
4).
Unlike wild-type MRL mice, the

2-microglobulin-deficient
animals
continued to gain weight after seroconversion (Fig.
5),
and no
inflammation was detected in the brains of infected

2-microglobulin-deficient
MRL mice at 6 or 8 weeks
postinfection (Fig.
2C). GFAP immunostaining
of brain sections of
these mice could not be distinguished from
that of brain sections from
uninfected controls (compare Fig.
2J and L). Immunostaining for BDV p40
showed the presence of many
infected neurons in the neocortex (Fig.
2F), the thalamus (Fig.
2I), and other brain regions (data not
shown) of the infected

2-microglobulin-deficient MRL mice.
Taken together these results
strongly support the concept that
BDV-induced neurological disease
in mice is a CD8
+
T-cell-dependent process.
 |
DISCUSSION |
Earlier studies suggested that mice are resistant to BDV-induced
disease in spite of the fact that the virus grows to high titers in the
brains of these animals (22). Mice of strain MRL were
moderately susceptible: they exhibited signs of hyperactivity when
infected with BDV that was passaged five times in mouse brains (40). Experiments described in this report now demonstrate
that mice (in particular mouse strain MRL) are highly susceptible to BDV-induced illness when infected at a very young age. The diseased mice exhibited prominent signs of neurological disease and had numerous
infiltrating lymphocytes in the brain. The discrepancy between the
earlier reports and our present results can be explained in part by the
fact that we used very young animals for our infection experiments.
Furthermore, we showed here that genetic factors have a great influence
on disease susceptibility. In the earlier studies, the animals were
usually not infected as newborns and only a few experiments were
performed with MRL mice.
Several of our observations collectively indicate that the BDV-induced
neurological disorder of mice is not due to direct cell damage caused
by the replicating virus but rather to indirect damage caused by the
host immune response. First, BDV grew to comparable levels in the
brains of diseased and nondiseased animals. Second, the most striking
histopathological feature of brains from diseased mice was the presence
of large numbers of infiltrating lymphocytes in the neocortex and other
brain regions. Third, by measuring serum antibodies to BDV we observed
that the first appearance of neurological signs of disease coincided
with the onset of the antiviral immune response. Fourth, and most
important, BDV infection of
2-microglobulin-deficient mice that lack
CD8+ T cells (25, 48) did not result in
neurological disease.
Histological analysis strongly indicated that most of the
above-described signs of neurological disease in our BDV-infected mice
were due to massive lymphocytic infiltration of the neocortex. We also
observed that in animals with terminal disease, the numbers of
BDV-infected neurons were usually rather low in brain regions with
multiple inflammatory foci, suggesting that the antiviral immune
response had successfully destroyed many infected neurons at the cost
of severe tissue damage. An interesting finding was that although
swelling of astrocytes was evident in brains of diseased mice, this
astrogliosis was not accompanied by increased GFAP immunoreactivity.
This was surprising considering the fact that most types of brain
injuries result in very strong astrogliosis with strong GFAP
immunoreactivity (16). In rats experimentally infected with
BDV, astrogliosis is usually also not observed in severely inflamed
brain regions (2a) but can be found in the hippocampus
formation of persistently infected animals that exhibit virus-induced
destruction of the dentate gyrus (14, 17).
An important conclusion from this work is that undefined genetic
factors determine the susceptibility of mice to BDV-induced disease.
The genetic background of MRL mice favored severe disease at a high
frequency, while the genetic background of C57BL/6 mice favored only a
more moderate course of the disease in a small percentage of infected
animals. Although the genetic backgrounds of CBA, C3H, and BALB/c mice
mediated disease induction at similar rates we observed clear
differences in the severity of BDV-induced disease among these strains.
The affected CBA and C3H mice, which, like MRL mice (31),
express the H-2k haplotype of the MHC class I
antigen, developed very severe disease, reminiscent of that of the MRL
mice. By contrast, the BDV-induced neurological disease in most
of the affected BALB/c (H-2d) or C57BL/6
(H-2b) mice took a more moderate course. These
results suggest that the severity of disease is controlled by alleles
of the MHC class I antigen, while the frequency at which BDV
induces neurological disease is controlled by other genetic traits. It
is of interest in this context that the genetic background of MRL mice
strongly predisposes for autoimmune disorders (1). Aged MRL
mice (older than 30 weeks) have enhanced titers of autoreactive
antibodies and spontaneously develop pancreatitis by a mechanism that
involves autoimmune CD4+ T cells (21). Since
high susceptibility to BDV was abrogated in
2-microglobulin-deficient MRL mice lacking CD8+ T cells
and since BDV-induced immunopathology occurred in 4- to 6-week-old
mice, it seems unlikely at first glance that autoimmunity and
susceptibility to BDV are mechanistically related. Nonetheless, it is
conceivable that the two phenotypes are the result of the same genetic
traits. If, as observed in the rat model (32, 33, 35),
activation of CD8+ T cells in BDV-infected mice is
dependent on help from CD4+ T cells, genetically determined
hypersensitivity of the latter cell population in MRL mice might lead
to a more potent response of CD8+ T cells and, in turn, to
neurological disease at an enhanced frequency. This hypothesis implies
that, depending on the antigenic stimulus, the hyperactive
CD4+ T cells of MRL mice might predispose to various types
of immunopathological disease.
A major difference between the well-established rat model system of
experimental Borna disease (17, 36) and the mouse system of
experimental Borna disease is that infection of adults induces
neurological disease in rats but not in mice (reference 22 and unpublished results). Furthermore, while
infection of newborns with BDV leads to immunological tolerance and
almost disease-free persistent infection in rats (10, 19),
we showed here that this constellation frequently leads to
immunopathology in mice. The molecular basis for this unexpected
behavior of the mouse is not well understood at present, but
differences in the kinetics of BDV spread in infected newborn rats and
mice could explain the different outcomes. In infected newborn rats,
BDV RNA was detected in the thymus as early as 3 days postinfection (39). Our recent experiments with infected newborn mice
indicated that BDV is initially highly neurotropic and that virus RNA
cannot be detected outside the CNS during the first 16 days after
infection by highly sensitive nested reverse transcription-PCR. If
confirmed, these results would suggest that viral antigen does not
appear in peripheral sites of infected newborn mice until the immune system has matured. This constellation is expected to induce a T-cell
response rather than tolerance.
It is unclear at present why BDV infections of newborn and adult mice
have different outcomes. One possibility is that in infected adult
mice, BDV multiplication is limited more strictly to the CNS than it is
in newborns. In this case, BDV antigen may not be present in sufficient
quantities at peripheral sites for efficient priming of T cells.
However, since infected adult mice readily produce antibodies to viral
proteins, this simple scenario does not seem to be correct.
Alternatively, infected adult mice may preferentially mount a Th2-type
immune response to BDV antigens, while infected newborn mice might
favor a Th1-type response. If true, the cytokine patterns induced by
BDV in adults and in newborns should be different. It should then also
be possible to induce susceptibility to BDV in adult mice by immunizing
with BDV antigen under conditions that favor a Th1-type immune
response.
Recent advances in gene targeting (8) were all pioneered in
the mouse, and a fast-growing number of mouse strains with defined
defects in the various branches of the immune system and the cytokine
network are becoming available (6). The mouse model for
BDV-induced neurological disorder presented here now allows, for the
first time, the performance of a genetic analysis of the Borna
disease-promoting processes. Mice with defined gene disruptions should
help to determine which of the BDV-induced neuropathological changes
are caused by the immune system and which lymphocytes contribute to
immunopathology. Our initial experiments with mutant mice have already
established that CD8+ T cells are instrumental in this
process. By using mice lacking perforin or other T-cell effector
molecules, it should now be possible to determine whether neurological
disease in MRL mice is due to cytotoxic T-cell activity in the brain or
results from cytokines secreted by the infiltrating lymphocytes.
 |
ACKNOWLEDGMENTS |
We thank Rosita Frank for expert technical assistance and
Hanspeter Pircher, Thomas Bilzer, Ulla Schultz, Georg Kochs, and Otto
Haller for technical advice and helpful comments on the manuscript.
This work was supported by a grant from the Zentrum für Klinische
Forschung I of the Universitätsklinikum Freiburg.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Virology, University of Freiburg, Hermann-Herder-Strasse 11, D-79008 Freiburg, Germany. Phone: 49-761-203-6579. Fax: 49-761-203-6562. E-mail: staeheli{at}ukl.uni-freiburg.de.
 |
REFERENCES |
| 1.
|
Andrews, B. S.,
R. A. Eisenberg,
A. N. Theofilopoulos,
S. Izui,
C. B. Wilson,
P. J. McConahey,
E. D. Murphy,
J. B. Roths, and F. J. Dixon.
1978.
Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains.
J. Exp. Med.
148:1198-1215[Abstract/Free Full Text].
|
| 2.
|
Ausubel, F.,
R. Brent,
R. Kingston,
D. Moore,
J. Seidman,
J. Smith, and K. Struhl.
1992.
In
Current protocols in molecular biology.
John Wiley & Sons, Inc., New York, N.Y.
|
| 2a.
| Bilzer, T. Personal communication.
|
| 3.
|
Bilzer, T., and L. Stitz.
1994.
Immune-mediated brain atrophy. CD8+ T cells contribute to tissue destruction during borna disease.
J. Immunol.
153:818-823[Abstract].
|
| 4.
|
Bode, L.
1995.
Human infections with Borna disease virus and potential pathogenic implications.
Curr. Top. Microbiol. Immunol.
190:103-130[Medline].
|
| 5.
|
Bode, L.,
W. Zimmermann,
R. Ferszt,
F. Steinbach, and H. Ludwig.
1995.
Borna disease virus genome transcribed and expressed in psychiatric patients.
Nat. Med.
1:232-236[Medline].
|
| 6.
|
Brandon, E. P.,
R. L. Idzerda, and G. S. McKnight.
1995.
Targeting the mouse genome: a compendium of knockouts.
Curr. Biol.
5:625-635[Medline].
|
| 7.
|
Briese, T.,
A. Schneemann,
A. J. Lewis,
Y. S. Park,
S. Kim,
H. Ludwig, and W. I. Lipkin.
1994.
Genomic organization of Borna disease virus.
Proc. Natl. Acad. Sci. USA
91:4362-4366[Abstract/Free Full Text].
|
| 8.
|
Capecchi, M. R.
1989.
Altering the genome by homologous recombination.
Science
144:1288-1292.
|
| 9.
|
Carbone, K. M.,
C. S. Duchala,
J. W. Griffin,
A. L. Kincaid, and O. Narayan.
1987.
Pathogenesis of Borna disease in rats: evidence that intra-axonal spread is the major route for virus dissemination and the determinant for disease incubation.
J. Virol.
61:3431-3440[Abstract/Free Full Text].
|
| 10.
|
Carbone, K. M.,
S. W. Park,
S. A. Rubin,
R. W. Waltrip, and G. B. Vogelsang.
1991.
Borna disease: association with a maturation defect in the cellular immune response.
J. Virol.
65:6154-6164[Abstract/Free Full Text].
|
| 11.
|
Carbone, K. M.,
S. A. Rubin,
A. M. Sierra Honigmann, and H. M. Lederman.
1993.
Characterization of a glial cell line persistently infected with Borna disease virus (BDV): influence of neurotrophic factors on BDV protein and RNA expression.
J. Virol.
67:1453-1460[Abstract/Free Full Text].
|
| 12.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 13.
|
de la Torre, J. C.
1994.
Molecular biology of Borna disease virus: prototype of a new group of animal viruses.
J. Virol.
68:7669-7675[Free Full Text].
|
| 14.
|
Deschl, U.,
L. Stitz,
S. Herzog,
K. Frese, and R. Rott.
1990.
Determination of immune cells and expression of MHC class II antigen in encephalitic lesions of experimental Borna virus disease.
Acta Neuropathol.
81:41-50[Medline].
|
| 15.
|
Dittrich, W.,
L. Bode,
H. Ludwig,
M. Kao, and K. Schneider.
1989.
Learning deficiencies in Borna disease virus-infected but clinically healthy rats.
Biol. Psychiatry
26:818-828[Medline].
|
| 16.
|
Eng, L. F., and R. S. Ghirnikar.
1994.
GFAP and astrogliosis.
Brain Pathol.
4:229-237[Medline].
|
| 17.
|
Gosztonyi, G., and H. Ludwig.
1995.
Borna disease neuropathology and pathogenesis.
Curr. Top. Microbiol. Immunol.
190:39-73[Medline].
|
| 17a.
| Hallensleben, W. Unpublished results.
|
| 18.
|
Hallensleben, W.,
M. Zocher, and P. Staeheli.
1997.
Borna disease virus is not sensitive to amantadine.
Arch. Virol.
142:2043-2048[Medline].
|
| 19.
|
Hirano, N.,
M. Kao, and H. Ludwig.
1983.
Persistent, tolerant or subacute infection in borna disease virus-infected rats.
J. Gen. Virol.
64:1521-1530[Abstract/Free Full Text].
|
| 20.
|
Junghans, R. P., and C. L. Anderson.
1996.
The protection receptor for IgG catabolism is the 2-microglobulin-containing neonatal intestinal transport receptor.
Proc. Natl. Acad. Sci. USA
93:5512-5516[Abstract/Free Full Text].
|
| 21.
|
Kanno, H.,
M. Nose,
J. Itoh,
Y. Taniguchi, and M. Kyogoku.
1992.
Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism.
Clin. Exp. Immunol.
89:68-73[Medline].
|
| 22.
|
Kao, M.,
H. Ludwig, and G. Gosztonyi.
1984.
Adaptation of Borna disease virus to the mouse.
J. Gen. Virol.
65:1845-1849[Abstract/Free Full Text].
|
| 23.
|
Kishi, M.,
T. Nakaya,
Y. Nakamura,
Q. Zhong,
K. Ikeda,
M. Senjo,
M. Kakinuma,
S. Kato, and K. Ikuta.
1995.
Demonstration of human Borna disease virus RNA in human peripheral blood mononuclear cells.
FEBS Lett.
364:293-297[Medline].
|
| 24.
|
Klein, R.,
I. Silos-Santiago,
R. J. Smeyne,
S. A. Lira,
R. Brambilla,
S. Bryant,
L. Zhang,
W. D. Snider, and M. Barbacid.
1994.
Disruption of the neurotrophin-3 receptor gene trkC eliminates Ia muscle afferents and results in abnormal movements.
Nature
368:249-251[Medline].
|
| 25.
|
Koller, B. H.,
P. Marrack,
J. W. Kappeler, and O. Smithies.
1990.
Normal development of mice deficient in b2M, MHC class I proteins, and CD8+ T cells.
Science
248:1227-1230[Abstract/Free Full Text].
|
| 26.
|
Ludwig, H.,
L. Bode, and G. Gosztonyi.
1988.
Borna disease: a persistent virus infection of the central nervous system.
Prog. Med. Virol.
35:107-151[Medline].
|
| 27.
|
Mangiarini, L.,
K. Sathasivam,
M. Seller,
B. Cozens,
A. Harper,
C. Hetherington,
M. Lawton,
Y. Trottier,
H. Lehrach,
S. W. Davies, and G. P. Bates.
1996.
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
Cell
87:493-506[Medline].
|
| 28.
|
Narayan, O.,
S. Herzog,
K. Frese,
H. Scheefers, and R. Rott.
1983.
Behavioral disease in rats caused by immunopathological responses to persistent borna disease virus in the brain.
Science
220:1401-1403[Abstract/Free Full Text].
|
| 29.
|
Narayan, O.,
S. Herzog,
K. Frese,
H. Scheefers, and R. Rott.
1983.
Pathogenesis of borna disease in rats: immune-mediated viral ophthalmoencephalopathy causing blindness and behavioral abnormalities.
J. Infect. Dis.
148:305-315[Medline].
|
| 30.
|
Panabieres, F.,
M. Piechaczyk,
B. Rainer,
C. Dani,
P. Fort,
S. Riaad,
L. Marty,
J. L. Imbach,
P. Jeanteur, and J. M. Blanchard.
1984.
Complete nucleotide sequence of the messenger RNA coding for chicken muscle glyceraldehyde-3-phosphate dehydrogenase.
Biochem. Biophys. Res. Commun.
118:767-773[Medline].
|
| 31.
|
Peng, S. L., and J. Craft.
1996.
MHC class I polymorphism in lupus-prone MRL/Mp mice.
Immunogenetics
44:407-408[Medline].
|
| 32.
|
Planz, O.,
T. Bilzer,
M. Sobbe, and L. Stitz.
1993.
Lysis of major histocompatibility complex class-I-bearing cells in borna disease virus induced degenerative encephalopathy.
J. Exp. Med.
178:163-174[Abstract/Free Full Text].
|
| 33.
|
Planz, O.,
T. Bilzer, and L. Stitz.
1995.
Immunopathologic role of T-cell subsets in Borna disease virus-induced progressive encephalitis.
J. Virol.
69:896-903[Abstract].
|
| 34.
|
Pritchard, C. A.,
L. Bolin,
R. Slattery,
R. Murray, and M. McMahon.
1996.
Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-raf protein kinase gene.
Curr. Biol.
6:614-617[Medline].
|
| 35.
|
Richt, J. A.,
L. Stitz,
H. Wekerle, and R. Rott.
1989.
Borna disease, a progressive meningoencephalomyelitis as a model for CD4+ T cell-mediated immunopathology in the brain.
J. Exp. Med.
170:1045-1050[Abstract/Free Full Text].
|
| 36.
|
Rott, R., and H. Becht.
1995.
Natural and experimental Borna disease in animals.
Curr. Top. Microbiol. Immunol.
190:17-30[Medline].
|
| 37.
|
Rott, R.,
S. Herzog,
K. Bechter, and K. Frese.
1991.
Borna disease, a possible hazard for man?
Arch. Virol.
118:143-149[Medline].
|
| 38.
|
Rott, R.,
S. Herzog,
B. Fleischer,
A. Winokur,
J. Amsterdam,
W. Dyson, and H. Koprowski.
1985.
Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders.
Science
228:755-756[Abstract/Free Full Text].
|
| 39.
|
Rubin, S. A.,
A. M. Sierra-Honigmann,
H. M. Lederman,
R. W. Waltrip, and J. J. C. Eiden.
1995.
Hematologic consequences of Borna disease virus infection of rat bone marrow and thymus stromal cells.
Blood
85:2762-2769[Abstract/Free Full Text].
|
| 40.
|
Rubin, S. A.,
R. W. Waltrip,
J. R. Bautista, and K. M. Carbone.
1993.
Borna disease virus in mice: host-specific differences in disease expression.
J. Virol.
67:548-552[Abstract/Free Full Text].
|
| 41.
|
Schneemann, A.,
P. A. Schneider,
R. A. Lamb, and W. I. Lipkin.
1995.
The remarkable coding strategy of Borna disease virus: a new member of the nonsegmented negative strand RNA viruses.
Virology
210:1-8[Medline].
|
| 42.
|
Shankar, V.,
M. Kao,
A. N. Hamir,
H. Sheng,
H. Koprowski, and B. Dietzschold.
1992.
Kinetics of virus spread and changes in levels of several cytokine mRNAs in the brain after intranasal infection of rats with Borna disease virus.
J. Virol.
66:992-998[Abstract/Free Full Text].
|
| 43.
|
Stitz, L.,
B. Dietzschold, and K. M. Carbone.
1995.
Immunopathogenesis of Borna disease.
Curr. Top. Microbiol. Immunol.
190:75-92[Medline].
|
| 44.
|
Stitz, L.,
M. Sobbe, and T. Bilzer.
1992.
Preventive effects of early anti-CD4 or anti-CD8 treatment on Borna disease in rats.
J. Virol.
66:3316-3323[Abstract/Free Full Text].
|
| 45.
|
Stitz, L.,
D. Soeder,
U. Deschl,
K. Frese, and R. Rott.
1989.
Inhibition of immune-mediated meningoencephalitis in persistently Borna disease virus-infected rats by cyclosporine A.
J. Immunol.
143:4250-4256[Abstract].
|
| 46.
|
Van de Woude, S.,
J. A. Richt,
M. C. Zink,
R. Rott,
O. Narayan, and J. E. Clements.
1990.
A borna virus cDNA encoding a protein recognized by antibodies in humans with behavioral diseases.
Science
250:1278-1281[Abstract/Free Full Text].
|
| 47.
|
Zheng, Y. M.,
M. K. Schafer,
E. Weihe,
H. Sheng,
S. Corisdeo,
Z. F. Fu,
H. Koprowski, and B. Dietzschold.
1993.
Severity of neurological signs and degree of inflammatory lesions in the brains of rats with Borna disease correlate with the induction of nitric oxide synthase.
J. Virol.
67:5786-5791[Abstract/Free Full Text].
|
| 48.
|
Zijlstra, M.,
M. Bix,
N. E. Simister,
J. M. Loring,
D. H. Raulet, and R. Jaenisch.
1990.
2-microglobulin deficient mice lack CD4 8+ cytolytic T cells.
Nature
344:742-746[Medline].
|
J Virol, May 1998, p. 4379-4386, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rinder, M., Ackermann, A., Kempf, H., Kaspers, B., Korbel, R., Staeheli, P.
(2009). Broad Tissue and Cell Tropism of Avian Bornavirus in Parrots with Proventricular Dilatation Disease. J. Virol.
83: 5401-5407
[Abstract]
[Full Text]
-
Richter, K., Hausmann, J., Staeheli, P.
(2009). Interferon-{gamma} Prevents Death of Bystander Neurons during CD8 T Cell Responses in the Brain. Am. J. Pathol.
174: 1799-1807
[Abstract]
[Full Text]
-
Cekinovic, D., Golemac, M., Pugel, E. P., Tomac, J., Cicin-Sain, L., Slavuljica, I., Bradford, R., Misch, S., Winkler, T. H., Mach, M., Britt, W. J., Jonjic, S.
(2008). Passive Immunization Reduces Murine Cytomegalovirus-Induced Brain Pathology in Newborn Mice. J. Virol.
82: 12172-12180
[Abstract]
[Full Text]
-
Baur, K., Rauer, M., Richter, K., Pagenstecher, A., Gotz, J., Hausmann, J., Staeheli, P.
(2008). Antiviral CD8 T Cells Recognize Borna Disease Virus Antigen Transgenically Expressed in either Neurons or Astrocytes. J. Virol.
82: 3099-3108
[Abstract]
[Full Text]
-
Ackermann, A., Kugel, D., Schneider, U., Staeheli, P.
(2007). Enhanced polymerase activity confers replication competence of Borna disease virus in mice. J. Gen. Virol.
88: 3130-3132
[Abstract]
[Full Text]
-
Richter, K., Baur, K., Ackermann, A., Schneider, U., Hausmann, J., Staeheli, P.
(2007). Pathogenic Potential of Borna Disease Virus Lacking the Immunodominant CD8 T-Cell Epitope. J. Virol.
81: 11187-11194
[Abstract]
[Full Text]
-
Ackermann, A., Staeheli, P., Schneider, U.
(2007). Adaptation of Borna Disease Virus to New Host Species Attributed to Altered Regulation of Viral Polymerase Activity. J. Virol.
81: 7933-7940
[Abstract]
[Full Text]
-
Schneider, U., Ackermann, A., Staeheli, P.
(2007). A Borna Disease Virus Vector for Expression of Foreign Genes in Neurons of Rodents. J. Virol.
81: 7293-7296
[Abstract]
[Full Text]
-
Williams, B. L., Yaddanapudi, K., Hornig, M., Lipkin, W. I.
(2007). Spatiotemporal Analysis of Purkinje Cell Degeneration Relative to Parasagittal Expression Domains in a Model of Neonatal Viral Infection. J. Virol.
81: 2675-2687
[Abstract]
[Full Text]
-
Schwardt, M., Mayer, D., Frank, R., Schneider, U., Eickmann, M., Planz, O., Wolff, T., Schwemmle, M.
(2005). The negative regulator of Borna disease virus polymerase is a non-structural protein. J. Gen. Virol.
86: 3163-3169
[Abstract]
[Full Text]
-
Hausmann, J., Pagenstecher, A., Baur, K., Richter, K., Rziha, H.-J., Staeheli, P.
(2005). CD8 T Cells Require Gamma Interferon To Clear Borna Disease Virus from the Brain and Prevent Immune System-Mediated Neuronal Damage. J. Virol.
79: 13509-13518
[Abstract]
[Full Text]
-
Hausmann, J., Baur, K., Engelhardt, K. R., Fischer, T., Rziha, H.-J., Staeheli, P.
(2005). Vaccine-induced protection against Borna disease in wild-type and perforin-deficient mice. J. Gen. Virol.
86: 399-403
[Abstract]
[Full Text]
-
Hofer, M., Hausmann, J., Staeheli, P., Pagenstecher, A.
(2004). Cerebral Expression of Interleukin-12 Induces Neurological Disease via Differential Pathways and Recruits Antigen-Specific T Cells in Virus-Infected Mice. Am. J. Pathol.
165: 949-958
[Abstract]
[Full Text]
-
Fassnacht, U., Ackermann, A., Staeheli, P., Hausmann, J.
(2004). Immunization with dendritic cells can break immunological ignorance toward a persisting virus in the central nervous system and induce partial protection against intracerebral viral challenge. J. Gen. Virol.
85: 2379-2387
[Abstract]
[Full Text]
-
Rauer, M., Gotz, J., Schuppli, D., Staeheli, P., Hausmann, J.
(2004). Transgenic Mice Expressing the Nucleoprotein of Borna Disease Virus in either Neurons or Astrocytes: Decreased Susceptibility to Homotypic Infection and Disease. J. Virol.
78: 3621-3632
[Abstract]
[Full Text]
-
Friedl, G., Hofer, M., Auber, B., Sauder, C., Hausmann, J., Staeheli, P., Pagenstecher, A.
(2004). Borna Disease Virus Multiplication in Mouse Organotypic Slice Cultures Is Site-Specifically Inhibited by Gamma Interferon but Not by Interleukin-12. J. Virol.
78: 1212-1218
[Abstract]
[Full Text]
-
Freude, S., Hausmann, J., Hofer, M., Pham-Mitchell, N., Campbell, I. L., Staeheli, P., Pagenstecher, A.
(2002). Borna Disease Virus Accelerates Inflammation and Disease Associated with Transgenic Expression of Interleukin-12 in the Central Nervous System. J. Virol.
76: 12223-12232
[Abstract]
[Full Text]
-
Nishino, Y., Kobasa, D., Rubin, S. A., Pletnikov, M. V., Carbone, K. M.
(2002). Enhanced Neurovirulence of Borna Disease Virus Variants Associated with Nucleotide Changes in the Glycoprotein and L Polymerase Genes. J. Virol.
76: 8650-8658
[Abstract]
[Full Text]
-
Hausmann, J., Schamel, K., Staeheli, P.
(2001). CD8+ T Lymphocytes Mediate Borna Disease Virus-Induced Immunopathology Independently of Perforin. J. Virol.
75: 10460-10466
[Abstract]
[Full Text]
-
Schamel, K., Staeheli, P., Hausmann, J.
(2001). Identification of the Immunodominant H-2Kk-Restricted Cytotoxic T-Cell Epitope in the Borna Disease Virus Nucleoprotein. J. Virol.
75: 8579-8588
[Abstract]
[Full Text]
-
Staeheli, P., Sentandreu, M., Pagenstecher, A., Hausmann, J.
(2001). Alpha/Beta Interferon Promotes Transcription and Inhibits Replication of Borna Disease Virus in Persistently Infected Cells. J. Virol.
75: 8216-8223
[Abstract]
[Full Text]
-
Carbone, K. M.
(2001). Borna Disease Virus and Human Disease. Clin. Microbiol. Rev.
14: 513-527
[Abstract]
[Full Text]
-
Fukuda, K., Takahashi, K., Iwata, Y., Mori, N., Gonda, K., Ogawa, T., Osonoe, K., Sato, M., Ogata, S.-i., Horimoto, T., Sawada, T., Tashiro, M., Yamaguchi, K., Niwa, S.-i., Shigeta, S.
(2001). Immunological and PCR Analyses for Borna Disease Virus in Psychiatric Patients and Blood Donors in Japan. J. Clin. Microbiol.
39: 419-429
[Abstract]
[Full Text]
-
Sauder, C., Hallensleben, W., Pagenstecher, A., Schneckenburger, S., Biro, L., Pertlik, D., Hausmann, J., Suter, M., Staeheli, P.
(2000). Chemokine Gene Expression in Astrocytes of Borna Disease Virus-Infected Rats and Mice in the Absence of Inflammation. J. Virol.
74: 9267-9280
[Abstract]
[Full Text]
-
Formella, S., Jehle, C., Sauder, C., Staeheli, P., Schwemmle, M.
(2000). Sequence Variability of Borna Disease Virus: Resistance to Superinfection May Contribute to High Genome Stability in Persistently Infected Cells. J. Virol.
74: 7878-7883
[Abstract]
[Full Text]
-
Hausmann, J., Hallensleben, W., de la Torre, J. C., Pagenstecher, A., Zimmermann, C., Pircher, H., Staeheli, P.
(1999). T cell ignorance in mice to Borna disease virus can be overcome by peripheral expression of the viral nucleoprotein. Proc. Natl. Acad. Sci. USA
96: 9769-9774
[Abstract]
[Full Text]
-
Lawrence, D. M. P., Vaughn, M. M., Belman, A. R., Cole, J. S., Rall, G. F.
(1999). Immune Response-Mediated Protection of Adult but Not Neonatal Mice from Neuron-Restricted Measles Virus Infection and Central Nervous System Disease. J. Virol.
73: 1795-1801
[Abstract]
[Full Text]